

# Jeffrey E Rubnitz

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/2339578/publications.pdf](https://exaly.com/author-pdf/2339578/publications.pdf)

Version: 2024-02-01

244  
papers

18,569  
citations

13078

68  
h-index

14801

128  
g-index

309  
all docs

309  
docs citations

309  
times ranked

17674  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute myeloid leukemias with <i>UBTF</i> tandem duplications are sensitive to menin inhibitors. <i>Blood</i> , 2024, 143, 619-630.	1.4	14
2	A new genomic framework to categorize pediatric acute myeloid leukemia. <i>Nature Genetics</i> , 2024, 56, 281-293.	20.4	7
3	Neurocognitive and psychosocial outcomes in survivors of childhood leukemia with Down syndrome. <i>Cancer Medicine</i> , 2024, 13, .	2.9	0
4	Genomic and global gene expression profiling in pediatric and young adult acute leukemia with <i>PICALM::MLL10</i> Fusion. <i>Leukemia</i> , 2024, 38, 981-990.	7.5	0
5	Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research. <i>Cancer Medicine</i> , 2024, 13, .	2.9	0
6	Optimized cytogenetic risk-group stratification of <i>KMT2A</i> -rearranged pediatric acute myeloid leukemia. <i>Blood Advances</i> , 2024, 8, 3200-3213.	5.4	0
7	Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML. <i>Blood Advances</i> , 2023, 7, 1769-1783.	5.4	7
8	Description of a novel subtype of acute myeloid leukemia defined by recurrent <i>CBFB</i> insertions. <i>Blood</i> , 2023, 141, 800-805.	1.4	2
9	Characterisation of children and adolescents with acute lymphoblastic leukaemia who presented without peripheral blood blasts at diagnosis. <i>British Journal of Haematology</i> , 2023, 200, 338-343.	2.7	0
10	Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML. <i>Bone Marrow Transplantation</i> , 2023, 58, 328-331.	2.4	5
11	<i>SAMHD1</i> single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia. <i>Blood Advances</i> , 2023, 7, 2538-2550.	5.4	5
12	Proteasome inhibition targets the <i>KMT2A</i> transcriptional complex in acute lymphoblastic leukemia. <i>Nature Communications</i> , 2023, 14, .	13.2	8
13	Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood <i>KMT2A</i> -Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group. <i>Journal of Clinical Oncology</i> , 2023, 41, 2963-2974.	15.4	18
14	Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia. <i>Blood Advances</i> , 2023, 7, 3651-3657.	5.4	2
15	Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia. <i>Leukemia</i> , 2023, 37, 1782-1791.	7.5	5
16	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. <i>Haematologica</i> , 2022, 107, 371-380.	3.5	6
17	CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. <i>Blood Advances</i> , 2022, 6, 521-527.	5.4	11
18	Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation. <i>Journal of Clinical Oncology</i> , 2022, 40, 772-783.	15.4	9

#	ARTICLE	IF	CITATIONS
19	Integrated Genomic Analysis Identifies <i>UBTF</i> Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 194-207.	5.8	44
20	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. <i>Blood Advances</i> , 2022, 6, 2824-2834.	5.4	5
21	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and <i>FLT3</i> -Internal Tandem Duplication. <i>Clinical Cancer Research</i> , 2022, 28, 2536-2546.	7.2	7
22	Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies. <i>Leukemia</i> , 2022, 36, 1951-1960.	7.5	14
23	Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. <i>Nature Communications</i> , 2022, 13, .	13.2	21
24	Clofarabine treatment of <i>KMT2A</i> infantile patients with acute lymphoblastic leukemia in St. Jude Total Therapy Study 16. <i>Blood Advances</i> , 2022, 6, 6131-6134.	5.4	3
25	Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study. <i>Leukemia</i> , 2021, 35, 2258-2273.	7.5	12
26	Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancer Discovery</i> , 2021, 11, 1440-1453.	14.2	158
27	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. <i>Nature Communications</i> , 2021, 12, 985.	13.2	37
28	Activity of venetoclax against relapsed acute undifferentiated leukemia. <i>Cancer</i> , 2021, 127, 2608-2611.	4.1	1
29	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease—Directed Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 326-337.	5.8	83
30	Global Proteomic Profiling of Pediatric AML: A Pilot Study. <i>Cancers</i> , 2021, 13, 3161.	3.8	7
31	How I treat pediatric acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1009-1018.	1.4	51
32	Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators. <i>Blood Cancer Discovery</i> , 2021, 2, 586-599.	5.8	22
33	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. <i>JAMA Network Open</i> , 2021, 4, e2128385.	6.0	7
34	Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML. <i>Blood</i> , 2021, 138, 3429-3429.	1.4	0
35	Liposome-Encapsulated Cytarabine and Daunorubicin (CPX-351) Induces Remission in Newly Diagnosed Pediatric Secondary Myeloid Malignancies. <i>Blood</i> , 2021, 138, 4415-4415.	1.4	0
36	Clofarabine-Based Chemotherapy for <i>KMT2A</i> Infantile Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3406-3406.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis. <i>Blood</i> , 2021, 138, 2295-2295.	1.4	0
38	Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, LBA-4-LBA-4.	1.4	0
39	78. Non-Invasive Prediction of Invasive Fungal Infection by Plasma-Based Microbial Cell-Free DNA Next-Generation Sequencing (mcfDNA NGS) in Pediatric Patients with Relapsed or Refractory Leukemia. <i>Open Forum Infectious Diseases</i> , 2021, 8, S51-S51.	0.9	0
40	A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 735-745.	7.5	68
41	Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer. <i>JAMA Oncology</i> , 2020, 6, 552.	7.3	89
42	DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML. <i>Cancers</i> , 2020, 12, 3024.	3.8	6
43	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 4800-4805.	4.1	14
44	Vancomycin Heteroresistance and Clinical Outcomes in Bloodstream Infections Caused by Coagulase-Negative Staphylococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.4	14
45	Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. <i>Lancet Oncology</i> , The, 2020, 21, 551-560.	10.8	103
46	Metabolic Acidosis in a Pediatric Patient with Leukemia and Fungal Infection. <i>Clinical Chemistry</i> , 2020, 66, 518-522.	3.5	2
47	Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2020, 136, 12-13.	1.4	3
48	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
49	Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. <i>Blood</i> , 2020, 136, 23-24.	1.4	3
50	Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2246-2256.	15.4	204
51	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. <i>Clinical and Translational Science</i> , 2019, 12, 641-647.	3.1	12
52	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2072-2081.	15.4	37
53	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. <i>Journal of Clinical Oncology</i> , 2019, 37, 3377-3391.	15.4	183
54	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 7320-7330.	7.2	16

#	ARTICLE	IF	CITATIONS
55	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. <i>Nature Communications</i> , 2019, 10, 2189.	13.2	29
56	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. , 2019, 7, 81.		77
57	Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. <i>Pharmacogenomics Journal</i> , 2019, 19, 305-314.	2.2	9
58	Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2019, 134, 285-285.	1.4	24
59	Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses. <i>Blood</i> , 2019, 134, 918-918.	1.4	1
60	Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 379-379.	1.4	2
61	Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 178-178.	1.4	0
62	A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome. <i>Blood</i> , 2019, 134, 1429-1429.	1.4	1
63	Bone mineral density in children with acute lymphoblastic leukemia. <i>Cancer</i> , 2018, 124, 1025-1035.	4.1	23
64	Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.4	5
65	Universal monitoring of minimal residual disease in acute myeloid leukemia. <i>JCI Insight</i> , 2018, 3, .	5.0	62
66	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	36.2	250
67	POST: A framework for set-based association analysis in high-dimensional data. <i>Methods</i> , 2018, 145, 76-81.	3.9	1
68	Acute Myeloid Leukemia in Children. , 2018, , 981-993.		2
69	Comprehensive Ara-C SNP Score Predicts Leukemic Cell Intracellular Ara-CTP Levels in Pediatric Acute Myeloid Leukemia Patients. <i>Pharmacogenomics</i> , 2018, 19, 1101-1110.	1.4	9
70	Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 854-863.	8.9	50
71	Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study. <i>Blood</i> , 2018, 132, 655-655.	1.4	3
72	Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Blood</i> , 2018, 132, 3966-3966.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Metabolomics Profiling Reveals Markers for Chemosensitivity and Clinical Outcomes in Pediatric AML Patients. <i>Blood</i> , 2018, 132, 1536-1536.	1.4	6
74	Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 26711-26723.	2.1	27
75	Genome-wide association analysis identifies SNPs predictive of <i>in vitro</i> leukemic cell sensitivity to cytarabine in pediatric AML. <i>Oncotarget</i> , 2018, 9, 34859-34875.	2.1	13
76	Pediatric LSC3 (pLSC3) Score Derived from DNMT3B-CD34-GPR56 As a Prognostic Tool to Predict AML Patient Outcome: Results from Two Independent Pediatric AML Cohorts. <i>Blood</i> , 2018, 132, 290-290.	1.4	1
77	Integrated Genome Wide Association Study (GWAS) Identifies SNPs Associated with Outcome in Pediatric AML. <i>Blood</i> , 2018, 132, 2758-2758.	1.4	2
78	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. <i>Leukemia and Lymphoma</i> , 2017, 58, 247-250.	1.4	5
79	Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. <i>Cancer</i> , 2017, 123, 3602-3608.	4.1	12
80	Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26632.	1.6	3
81	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 294-302.	1.6	17
82	Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. <i>Cancer</i> , 2017, 123, 3791-3798.	4.1	39
83	RelA Mutant <i>Enterococcus faecium</i> with Multiantibiotic Tolerance Arising in an Immunocompromised Host. <i>MBio</i> , 2017, 8, .	4.4	80
84	Current Management of Childhood Acute Myeloid Leukemia. <i>Paediatric Drugs</i> , 2017, 19, 1-10.	3.2	66
85	POST: A framework for set-based association analysis in high-dimensional data. , 2017, , .		0
86	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2017, 128, 369-380.	8.2	39
87	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1546-1551.	1.6	29
88	Evaluation of artemisinins for the treatment of acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1231-1243.	2.4	44
89	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 4094-4101.	15.4	98
90	The genomic landscape of core-binding factor acute myeloid leukemias. <i>Nature Genetics</i> , 2016, 48, 1551-1556.	20.4	222

#	ARTICLE	IF	CITATIONS
91	Clinical significance of <i>in vivo</i> cytarabine-induced gene expression signature in AML. <i>Leukemia and Lymphoma</i> , 2016, 57, 909-920.	1.4	7
92	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 179-179.	1.4	0
93	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. <i>Blood</i> , 2016, 128, 2838-2838.	1.4	0
94	Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot Study. <i>PLoS ONE</i> , 2015, 10, e0135904.	2.5	9
95	Clinical Impact of Additional Cytogenetic Aberrations, <i>ckIT</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 4247-4258.	15.4	77
96	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. <i>Journal of Clinical Oncology</i> , 2015, 33, 610-615.	15.4	57
97	Natural killer cell therapy in children with relapsed leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1468-1472.	1.6	42
98	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. <i>Lancet Oncology</i> , The, 2015, 16, 465-474.	10.8	183
99	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	15.4	295
100	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. <i>British Journal of Haematology</i> , 2015, 168, 94-101.	2.7	32
101	Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML. <i>Blood</i> , 2015, 126, 1345-1345.	1.4	2
102	Acute Appendicitis in Children with Leukemia: Unique Diagnostic Process, Management, and Outcome. <i>Blood</i> , 2015, 126, 4872-4872.	1.4	3
103	Methylation of DNMT3B Strongly Associates with the Methylome, Cytogenetic Risk Groups, and Prognosis of Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2434-2434.	1.4	0
104	Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?. <i>Expert Review of Hematology</i> , 2014, 7, 427-429.	2.1	12
105	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 1985-1992.	4.1	54
106	Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2014, 120, 1514-1519.	4.1	61
107	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 949-959.	15.4	288
108	Definition of cure in childhood acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 2490-2496.	4.1	13

#	ARTICLE	IF	CITATIONS
109	Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. <i>Haematologica</i> , 2014, 99, 299-307.	3.5	35
110	An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? a Report from Children's Oncology Group Protocols AAML0531 and 03P1 and St Jude Children's Research Hospital Protocol AML02. <i>Blood</i> , 2014, 124, 277-277.	1.4	2
111	Targeted Inhibition of the MLL Transcriptional Complex By Proteasome Inhibitors Elicits a High Response Rate in Relapsed/Refractory MLL Rearranged Leukemia. <i>Blood</i> , 2014, 124, 972-972.	1.4	8
112	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2014, 124, 3722-3722.	1.4	0
113	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. <i>Blood</i> , 2014, 124, 481-481.	1.4	0
114	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 369-378.	2.4	36
115	Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 4036-4043.	4.1	42
116	Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2013, 119, 2061-2066.	4.1	27
117	Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1161-1164.	1.6	23
118	Voriconazole Prophylaxis in Children With Cancer. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e451-e455.	2.0	23
119	Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD-Positive Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 5758-5768.	7.2	88
120	Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy. <i>Clinical Cancer Research</i> , 2013, 19, 1620-1627.	7.2	61
121	<i>RRM1</i> and <i>RRM2</i> Pharmacogenetics: Association with Phenotypes in HapMap Cell Lines and Acute Myeloid Leukemia Patients. <i>Pharmacogenomics</i> , 2013, 14, 1449-1466.	1.4	29
122	Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. <i>Blood</i> , 2013, 121, 4366-4376.	1.4	43
123	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Münster AML-study group. <i>Blood</i> , 2013, 122, 2704-2713.	1.4	89
124	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. <i>Blood</i> , 2013, 122, 490-490.	1.4	0
125	Ontogeny and Sorafenib Metabolism. <i>Clinical Cancer Research</i> , 2012, 18, 5788-5795.	7.2	40
126	Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007. <i>Journal of Clinical Oncology</i> , 2012, 30, 2005-2012.	15.4	106



#	ARTICLE	IF	CITATIONS
127	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012, 119, e67-e75.	1.4	66
128	How I treat pediatric acute myeloid leukemia. <i>Blood</i> , 2012, 119, 5980-5988.	1.4	81
129	Childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 259-276.	2.7	69
130	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. <i>Blood</i> , 2012, 120, 468-472.	1.4	178
131	An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 683-697.	16.8	217
132	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3625-3632.	15.4	190
133	Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 921-929.	3.7	57
134	Effect of body mass index on the outcome of children with acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 5989-5996.	4.1	59
135	Treatment outcome in older patients with childhood acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 6253-6259.	4.1	32
136	Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. <i>British Journal of Haematology</i> , 2012, 156, 275-279.	2.7	16
137	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Munster AML Study Group. <i>Blood</i> , 2012, 120, 2516-2516.	1.4	0
138	Isolated Nasal Septum Necrosis Caused by <i>Aspergillus flavus</i> in an Immunocompromised Child. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 627-629.	2.0	7
139	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. <i>Blood</i> , 2011, 117, 7102-7111.	1.4	59
140	High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. <i>Blood</i> , 2011, 118, 223-230.	1.4	160
141	Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia. <i>Leukemia Research</i> , 2011, 35, 1321-1329.	1.1	21
142	Spinal epidural lipomatosis in children with hematologic malignancies. <i>Annals of Hematology</i> , 2011, 90, 1067-1074.	1.8	10
143	Randomized trial of 2 dosages of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 1313-1320.	4.1	13
144	Identification of Predictive Markers of Cytarabine Response in AML by Integrative Analysis of Gene-Expression Profiles with Multiple Phenotypes. <i>Pharmacogenomics</i> , 2011, 12, 327-339.	1.4	28

#	ARTICLE	IF	CITATIONS
145	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 386-391.	15.4	123
146	Genetic Variants in Cytosolic 5â€²-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 9-23.	2.4	51
147	Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 3293-3300.	15.4	143
148	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. <i>Journal of the National Cancer Institute</i> , 2011, 103, 893-905.	6.4	50
149	Acute Megakaryoblastic Leukemia Without <i>GATA1</i> Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e230-e233.	15.4	15
150	Transcriptome Sequence Analysis of Pediatric Acute Megakaryoblastic Leukemia Identifies An <i>Inv(16)(p13.3;q24.3)</i> -Encoded <i>CBFA2T3-GLIS2</i> Fusion Protein As a Recurrent Lesion in 39% of Non-Infant Cases: A Report From the St. Jude Children's Research Hospital â€” Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011, 118, 757-757.	1.4	7
151	Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. <i>Cancer</i> , 2010, 116, 98-105.	4.1	25
152	Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)â€”rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. <i>Blood</i> , 2010, 116, 2644-2650.	1.4	147
153	Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia. <i>European Journal of Paediatric Neurology</i> , 2010, 14, 78-79.	1.5	13
154	Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 5499-5510.	7.2	74
155	NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 955-959.	15.4	574
156	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. <i>Lancet Oncology</i> , The, 2010, 11, 543-552.	10.8	524
157	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1073-1073.	1.4	3
158	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 498-498.	1.4	0
159	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. <i>Blood</i> , 2010, 116, 849-849.	1.4	0
160	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. <i>Blood</i> , 2010, 116, 495-495.	1.4	1
161	Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12944-12949.	7.6	172
162	PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. <i>Bioinformatics</i> , 2009, 25, 2013-2019.	4.2	16

#	ARTICLE	IF	CITATIONS
163	Cutaneous Infection Caused by <i>Macrophomina phaseolina</i> in a Child with Acute Myeloid Leukemia. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1969-1972.	4.4	32
164	Health-related quality of life in adolescents at the time of diagnosis with osteosarcoma or acute myeloid leukemia. <i>European Journal of Oncology Nursing</i> , 2009, 13, 156-163.	2.2	39
165	Minimal Residual Disease Quantitation in Acute Myeloid Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S281-S285.	1.8	42
166	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. <i>New England Journal of Medicine</i> , 2009, 360, 2730-2741.	30.1	1,079
167	Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. <i>Lancet Oncology</i> , The, 2009, 10, 147-156.	10.8	872
168	Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. <i>Blood</i> , 2009, 113, 5083-5089.	1.4	159
169	Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. <i>Blood</i> , 2009, 114, 3764-3768.	1.4	83
170	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. <i>Blood</i> , 2009, 114, 2489-2496.	1.4	393
171	Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2009, 114, 114-114.	1.4	3
172	Minimal Residual Disease-Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial. <i>Blood</i> , 2009, 114, 16-16.	1.4	0
173	5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2009, 114, 593-593.	1.4	0
174	Childhood Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2008, 9, 95-105.	3.1	27
175	Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2008, 50, 542-548.	1.6	4
176	Baseline mannose binding lectin levels may not predict infection among children with leukemia. <i>Pediatric Blood and Cancer</i> , 2008, 50, 866-868.	1.6	10
177	Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. <i>Cancer</i> , 2008, 113, 376-382.	4.1	88
178	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. <i>Cancer</i> , 2008, 113, 522-529.	4.1	85
179	Prospective Analysis of <i>TEL</i> Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2186-2191.	15.4	79
180	Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1207.	7.0	268

#	ARTICLE	IF	CITATIONS
181	Pharmacogenetics of Deoxycytidine Kinase: Identification and Characterization of Novel Genetic Variants. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 935-945.	2.4	77
182	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. <i>Lancet, The</i> , 2007, 370, 240-250.	12.1	562
183	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007, 109, 926-935.	1.4	420
184	Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. <i>Cancer</i> , 2007, 109, 157-163.	4.1	88
185	Effect of race on outcome of white and black children with acute myeloid leukemia: The St. Jude experience. <i>Pediatric Blood and Cancer</i> , 2007, 48, 10-15.	1.6	46
186	Molecular genetics of acute lymphoblastic leukemia. , 2006, , 272-297.		0
187	Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2006, 108, 3302-3304.	1.4	87
188	Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. <i>Blood</i> , 2006, 108, 3997-4002.	1.4	91
189	Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. <i>Pediatric Blood and Cancer</i> , 2006, 47, 931-935.	1.6	51
190	Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome. <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 50-57.	0.9	44
191	Impact of age on outcome of pediatric acute myeloid leukemia. <i>Cancer</i> , 2006, 106, 2495-2502.	4.1	52
192	Syndrome of Inappropriate Secretion of Anti-Diuretic Hormone in Children with Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2006, 108, 4474-4474.	1.4	2
193	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2005, 103, 368-376.	4.1	79
194	Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2005, 44, 138-141.	1.6	20
195	Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2005, 44, 63-69.	1.6	35
196	Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 7936-7941.	15.4	70
197	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. <i>Blood</i> , 2005, 105, 4752-4758.	1.4	205
198	Gene expression profiling of pediatric acute myelogenous leukemia. <i>Blood</i> , 2004, 104, 3679-3687.	1.4	407

#	ARTICLE	IF	CITATIONS
199	Death during induction therapy and first remission of acute leukemia in childhood. <i>Cancer</i> , 2004, 101, 1677-1684.	4.1	127
200	Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. <i>Leukemia Research</i> , 2004, 28, 349-352.	1.1	20
201	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIII B at St Jude Children's Research Hospital. <i>Blood</i> , 2004, 104, 2690-2696.	1.4	415
202	Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 3084-3091.	15.4	180
203	Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2003, 123, 243-252.	2.7	122
204	Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. <i>Cancer Treatment Reviews</i> , 2003, 29, 31-44.	8.0	43
205	Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2001.	7.0	160
206	MRD in AML: it's time to face the FACS. <i>Blood</i> , 2003, 101, 3341-3341.	1.4	1
207	Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 4217-4224.	15.4	65
208	Risk Factors for Traumatic and Bloody Lumbar Puncture in Children With Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2001.	7.0	138
209	Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 2302-2309.	15.4	178
210	TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. <i>Current Opinion in Hematology</i> , 2002, 9, 345-352.	2.6	61
211	Skeletal Manifestations of Pediatric Acute Megakaryoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 561-565.	0.6	22
212	Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 43-47.	1.4	45
213	Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 52-58.	1.4	240
214	Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 2399-2402.	1.4	174
215	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 419-428.	2.4	44
216	Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. <i>Blood</i> , 2001, 97, 3727-3732.	1.4	195

#	ARTICLE	IF	CITATIONS
217	Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10338-10343.	7.6	57
218	Safety of Lumbar Puncture for Children With Acute Lymphoblastic Leukemia and Thrombocytopenia. JAMA - Journal of the American Medical Association, 2000, 284, 2222.	7.0	157
219	Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2000, 28, 227-232.	3.3	15
220	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 3381-3384.	1.4	181
221	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 2691-2696.	1.4	412
222	Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2000, 18, 3273-3279.	15.4	214
223	Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2000, 18, 1525-1532.	15.4	156
224	Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 2691-2696.	1.4	14
225	Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2000, 28, 227-232.	3.3	0
226	Childhood Acute Lymphoblastic Leukemia With the <i>MLL-ENL</i> Fusion and t(11;19)(q23;p13.3) Translocation. Journal of Clinical Oncology, 1999, 17, 191-191.	15.4	102
227	Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 1999, 17, 818-818.	15.4	129
228	p27KIP1 Deletions in Childhood Acute Lymphoblastic Leukemia. Neoplasia, 1999, 1, 253-261.	5.3	37
229	High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet, The, 1999, 354, 34-39.	12.1	391
230	Molecular diagnostics in the treatment of leukemia. Current Opinion in Hematology, 1999, 6, 229.	2.6	18
231	Hyperdiploid Acute Lymphoblastic Leukemia With 51 to 65 Chromosomes: A Distinct Biological Entity With a Marked Propensity to Undergo Apoptosis. Blood, 1999, 93, 315-320.	1.4	1
232	Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet, The, 1998, 351, 550-554.	12.1	404
233	Molecular Genetics of Childhood Leukemias. Journal of Pediatric Hematology/Oncology, 1998, 20, 1-11.	0.6	58
234	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	1.4	184

#	ARTICLE	IF	CITATIONS
235	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998, 92, 411-415.	1.4	6
236	Recent advances in the biology and treatment of childhood acute lymphoblastic leukemia. <i>Current Opinion in Hematology</i> , 1997, 4, 233-241.	2.6	20
237	Case-Control Study Suggests a Favorable Impact of TEL Rearrangement in Patients With B-Lineage Acute Lymphoblastic Leukemia Treated With Antimetabolite-Based Therapy: A Pediatric Oncology Group Study. <i>Blood</i> , 1997, 89, 1143-1146.	1.4	91
238	Childhood Acute Lymphoblastic Leukemia. <i>Oncologist</i> , 1997, 2, 374-380.	4.1	21
239	Correction of deletions in mammalian cells by gene conversion. <i>Somatic Cell and Molecular Genetics</i> , 1987, 13, 183-190.	0.7	10
240	Constitutive behavior of methionyl-tRNA synthetase compared to repressible behavior of methionine adenosyltransferase in mammalian cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1981, 677, 269-273.	2.5	4
241	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. <i>SSRN Electronic Journal</i> , 0, , .	0.3	0
242	Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods. <i>Cancer</i> , 0, , .	4.1	1
243	Pharmacogenomic Score Effectively Personalizes Treatment of Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 0, , .	7.2	0
244	Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies. <i>Blood</i> , 0, , .	1.4	0